In part 2 of this update, the authors present the latest recommendations for respiratory, cardiac, bone health and osteoporosis, and orthopaedic and surgical management for boys and young men. It also acknowledges the effects of long-term glucocorticoid use on the natural history of DMD and the need for care guidance across the lifespan as patients live longer. They acknowledge the management of DMD looks set to change substantially as new genetic and molecular therapies become available.
Birnkrant, D. J. 2018. Duchenne Muscular Dystrophy Diagnosis and Management: Part 2 - respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurology 17 (4) p 347-361.
Contact the Library for a copy